MCID: SCL009
MIFTS: 47

Sclerosing Cholangitis

Categories: Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Sclerosing Cholangitis

MalaCards integrated aliases for Sclerosing Cholangitis:

Name: Sclerosing Cholangitis 12 75 59 15 17
Primary Sclerosing Cholangitis 72
Cholangitis, Sclerosing 72
Fibrosing Cholangitis 12

Classifications:

Orphanet: 59  
Rare hepatic diseases


External Ids:

Disease Ontology 12 DOID:14268
MeSH 44 D015209
SNOMED-CT 68 4032000
ICD10 33 K83.0
UMLS via Orphanet 73 C0008313
Orphanet 59 ORPHA447771
UMLS 72 C0008313 C0566602

Summaries for Sclerosing Cholangitis

MalaCards based summary : Sclerosing Cholangitis, also known as primary sclerosing cholangitis, is related to sclerosing cholangitis, neonatal and autoimmune hepatitis, and has symptoms including icterus An important gene associated with Sclerosing Cholangitis is CLDN1 (Claudin 1), and among its related pathways/superpathways are Cell adhesion molecules (CAMs) and Bile secretion. The drugs Prednisone and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and t cells, and related phenotypes are immune system and liver/biliary system

Wikipedia : 75 Primary sclerosing cholangitis (PSC) is a long-term progressive disease of the liver and gallbladder... more...

Related Diseases for Sclerosing Cholangitis

Diseases in the Sclerosing Cholangitis family:

Cholangitis, Primary Sclerosing Secondary Sclerosing Cholangitis

Diseases related to Sclerosing Cholangitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 504)
# Related Disease Score Top Affiliating Genes
1 sclerosing cholangitis, neonatal 35.3 DCDC2 CLDN1
2 autoimmune hepatitis 32.1 HLA-DRB1 GPT GGT1
3 portal hypertension 31.7 TNF GPT ALB
4 cholangitis, primary sclerosing 31.6 PRTN3 NR1I2 GPT GPBAR1 GGT1 FUT2
5 bilirubin metabolic disorder 31.2 GPT GGT1 ALB
6 cholecystitis 31.2 GPT ALB ABCB4
7 acquired immunodeficiency syndrome 31.2 TNF HLA-B ALB
8 echinococcosis 31.1 TNF HLA-DRB1 HLA-B
9 hepatitis 31.0 TNF GPT GGT1 CLDN1
10 hepatitis a 31.0 TNF GPT ALB
11 hepatic encephalopathy 30.9 TNF GPT ALB
12 graft-versus-host disease 30.9 TNF HLA-DRB1 HLA-B
13 viral hepatitis 30.8 TNF GPT GGT1 ALB
14 hepatitis c 30.7 TNF GPT GGT1 CLDN1
15 biliary atresia 30.6 NR1H4 GPT ALB
16 microscopic polyangiitis 30.6 TNF HLA-DRB1
17 gastroenteritis 30.5 TNF FUT2 ALB
18 extrahepatic cholestasis 30.5 GPT GGT1 ABCB4
19 palindromic rheumatism 30.3 TNF PRTN3 HLA-DRB1
20 alcoholic hepatitis 30.3 TNF GPT ALB
21 pancreas disease 30.3 TNF CFTR ALB
22 diarrhea 30.2 CFTR CD40LG ALB
23 cholelithiasis 30.2 NR1H4 GPT ALB ABCB4
24 gastrointestinal system disease 30.1 TNF NR1I2 GGT1 ALB
25 choledocholithiasis 30.1 GPT ALPP ALB ABCB4
26 atp8b1 deficiency 30.1 NR1H4 ABCB11
27 obstructive jaundice 29.8 TNF GPT GPBAR1 GGT1 ALPP ALB
28 schistosomiasis 29.7 TNF CD40LG ALB
29 rheumatic disease 29.7 TNF HLA-DRB1 HLA-B CD40LG
30 vasculitis 29.6 TNF PRTN3 HLA-B CTSG CD40LG
31 progressive familial intrahepatic cholestasis 29.5 NR1H4 ABCB4 ABCB11
32 psoriatic arthritis 29.4 TNF HLA-DRB1 HLA-B
33 rheumatoid arthritis 29.3 TNF PRTN3 HLA-DRB1 HLA-B CD40LG
34 cholestasis 28.9 NR1I2 NR1H4 GPT GGT1 ALPP ABCB4
35 systemic lupus erythematosus 28.9 TNF PRTN3 HLA-DRB1 CTSG CD40LG ALB
36 bile duct disease 28.6 NR1I2 NR1H4 GPT GPBAR1 GGT1 ALB
37 cholangitis 28.6 TNF PRTN3 HLA-DRB1 HLA-B GPT GPBAR1
38 biliary tract disease 28.5 NR1I2 NR1H4 GPBAR1 GGT1 ALB ABCB4
39 liver disease 28.5 TNF NR1H4 GPT GGT1 ALPP ALB
40 intrahepatic cholestasis of pregnancy 27.8 TNF NR1I2 NR1H4 GPBAR1 GGT1 ABCB4
41 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 13.1
42 secondary sclerosing cholangitis 12.8
43 igg4-related sclerosing cholangitis 12.6
44 pancreatitis, sclerosing cholangitis, and sicca complex 12.5
45 isolated neonatal sclerosing cholangitis 12.4
46 cholangiocarcinoma 11.9
47 bile duct cancer 11.9
48 immunodeficiency 14 11.4
49 intrahepatic cholangiocarcinoma 11.2
50 ulcerative colitis 11.2

Graphical network of the top 20 diseases related to Sclerosing Cholangitis:



Diseases related to Sclerosing Cholangitis

Symptoms & Phenotypes for Sclerosing Cholangitis

UMLS symptoms related to Sclerosing Cholangitis:


icterus

MGI Mouse Phenotypes related to Sclerosing Cholangitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.65 ABCB4 CD40LG CFTR CTSG FUT2 GGT1
2 liver/biliary system MP:0005370 9.28 ABCB11 ABCB4 ALB CFTR CTSG GPBAR1

Drugs & Therapeutics for Sclerosing Cholangitis

Drugs for Sclerosing Cholangitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
7
Ofloxacin Approved Phase 4 82419-36-1 4583
8
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
9
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
10
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
11 Immunologic Factors Phase 4
12 Immunosuppressive Agents Phase 4
13 Anti-Inflammatory Agents Phase 4
14 Hormone Antagonists Phase 4
15 Hormones Phase 4
16 glucocorticoids Phase 4
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
18 Immunoglobulin G Phase 4
19 Prednisolone acetate Phase 4
20 Methylprednisolone Acetate Phase 4
21 Antineoplastic Agents, Hormonal Phase 4
22 Anti-Bacterial Agents Phase 4
23 Antibiotics, Antitubercular Phase 4
24 Cytochrome P-450 Enzyme Inhibitors Phase 4
25 Renal Agents Phase 4
26 Antitubercular Agents Phase 4
27 Topoisomerase Inhibitors Phase 4
28 Anti-Infective Agents, Urinary Phase 4
29 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
30 Antibodies Phase 4
31 Antibodies, Monoclonal Phase 4
32 Immunoglobulins Phase 4
33
Bezafibrate Approved, Investigational Phase 3 41859-67-0 39042
34
Vancomycin Approved Phase 2, Phase 3 1404-90-6 441141 14969
35 Lipid Regulating Agents Phase 3
36 Hypolipidemic Agents Phase 3
37
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
38
Curcumin Approved, Experimental, Investigational Phase 1, Phase 2 458-37-7 969516
39
chenodeoxycholic acid Approved Phase 2 474-25-9 10133
40
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
41
Sulfasalazine Approved Phase 2 599-79-1 5359476 5353980
42
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
43
Ursodeoxycholic acid Approved, Investigational Phase 1, Phase 2 128-13-2 31401
44
Fenofibrate Approved Phase 1, Phase 2 49562-28-9 3339
45
Fluorouracil Approved Phase 2 51-21-8 3385
46
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
47
Gemcitabine Approved Phase 2 95058-81-4 60750
48
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
49
Pancrelipase Approved, Investigational Phase 2 53608-75-6
50
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis. Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
2 A Study of Safety and Efficacy of Leflunomide for Maintenance of Remission in IgG4 Related Disease Completed NCT02703194 Phase 4 Prednisone;Leflunomide
3 Randomized Trial of Short Antibiotic Course to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
4 A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology Active, not recruiting NCT02910375 Phase 4
5 Multicenter Randomized Trial Comparing Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
6 Probiotics in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease- a Randomized Placebo-Controlled Cross-Over Trial Unknown status NCT00161148 Phase 3 Probiotics
7 The Effect of Bezafibrate on Cholestatic Itch Unknown status NCT02701166 Phase 3 Bezafibrate;Placebo
8 Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid
9 Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Completed NCT01802073 Phase 3 Oral Vancomycin
10 Diagnosis of Intraepithelial Neoplasia in Patients With Long Standing Ulcerative Colitis With Chromoscopic Guided Endomicroscopy Completed NCT00352404 Phase 3
11 Digital SpyGlass Cholangioscopy Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy Completed NCT02967926 Phase 3
12 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis Recruiting NCT03890120 Phase 3 Cilofexor;Placebo
13 Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing Norursodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis Recruiting NCT03872921 Phase 3 Norursocholic Acid
14 A Prospective, Randomized, Multi-centered, Placebo-controlled Clinical Trial of Oral Vanycomycin in Adults With Primary Sclerosing Cholangitis Recruiting NCT03710122 Phase 2, Phase 3 Vancomycin
15 A Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease Withdrawn NCT03035058 Phase 3 Vedolizumab;Placebo
16 Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis Completed NCT00004762 Phase 2 cladribine
17 A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis Completed NCT02704364 Phase 2
18 A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing Cholangitis Completed NCT02061540 Phase 2 LUM001
19 PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT02653625 Phase 2 Cenicriviroc 150 mg
20 An Open-Label Pilot Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis Completed NCT02978339 Phase 1, Phase 2 Curcumin
21 A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT01672853 Phase 2
22 Double-blind,Randomized, Placebo-controlled, Phase II Dose-finding Study Comparing Different Doses of Norursodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis Completed NCT01755507 Phase 2 norUDCA;Placebo
23 A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC). Completed NCT02239211 Phase 2 BTT1023
24 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis Completed NCT02177136 Phase 2 OCA;Placebo
25 Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis. Completed NCT02424175 Phase 1, Phase 2
26 A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Active Pouchitis Completed NCT00583076 Phase 2 AST-120
27 Rituximab (RTX) for IgG4-related Disease (IgG4-RD): a Prospective,Open-label Trial Completed NCT01584388 Phase 1, Phase 2 Rituximab
28 Phase 2 Study of Mitomycin C Therapy for Biliary Strictures in Patients With Primary Sclerosing Cholangitis Recruiting NCT01688024 Phase 2 Mitomycin C;Normal saline
29 A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC) Recruiting NCT03333928 Phase 2 HTD1801;Placebo
30 A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC) Recruiting NCT03561584 Phase 2 Sulfasalazine;Placebo
31 An Efficacy Trial of Low Dose All-trans Retinoic Acid (ATRA) in Patients With Primary Sclerosing Cholangitis Recruiting NCT03359174 Phase 2 All-trans retinoic acid
32 An Adaptive,Multicentre, Phase IIa, Multi-disease Trial Investigating the Safety & Activity of a Single Infusion of Selected Mesenchymal Stromal Cells in the Treatment of Patients With Primary Sclerosing Cholangitis & Autoimmune Hepatitis Recruiting NCT02997878 Phase 1, Phase 2
33 Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach Recruiting NCT01988506 Phase 2 Interleukin 2
34 A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis Active, not recruiting NCT02943460 Phase 2 Cilofexor;Placebo to match Cilofexor
35 Intra-arterial Injection of Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis Active, not recruiting NCT03516006 Phase 1, Phase 2 UCMSC;UDCA
36 A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC) Not yet recruiting NCT04024813 Phase 2 Seladelpar;Placebo to match Seladelpar
37 A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid (UDCA) in Adolescents With Primary Sclerosing Cholangitis (PSC) Not yet recruiting NCT03678480 Phase 2 HTD1801;Ursodeoxycholic Acid
38 Investigation of the Activity of Vidofludimus Calcium, a Novel, Orally Available, Small Molecule Inhibitor of Dihydroorotate Dehydrogenase, as a Treatment for Primary Sclerosing Cholangitis (PSC) Not yet recruiting NCT03722576 Phase 2 Vidofludimus calcium
39 Pilot Study of Fenofibrate in Primary Sclerosing Cholangitis Terminated NCT01142323 Phase 1, Phase 2 fenofibrate
40 A Randomized, Open-label, Phase 2 Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC) Terminated NCT03394781 Phase 2 DUR-928
41 Open Label, Phase II Investigation of Thalidomide for the Treatment of Primary Sclerosing Cholangitis Terminated NCT00953615 Phase 2 Thalidomide
42 Definitive Chemoradiation With Gemcitabine and Continuous 5- FU (Fluorouracil)Followed by High Dose Rate Brachytherapy or Stereotactic Body Radiation Therapy Boost in Locally Advanced Intra or Extrahepatic Cholangiocarcinoma Terminated NCT00983541 Phase 2 Fluorouracil (5-FU);Gemcitabine
43 A Pilot Study of Oral Hymecromone to Treat Adults With Primary Sclerosing Cholangitis Withdrawn NCT02780752 Phase 1, Phase 2 hymecromone
44 Primary Sclerosing Cholangitis: Value of Computerized Tomographic Cholangiography and Intraductal Volumetric Measurement in Determining the Prognosis Withdrawn NCT00588458 Phase 2
45 Phase 1 Study of Intrahepatic Reinfusion of Highly Purified CD133+ Stem Cells in Patients With End-Stage Liver Disease Unknown status NCT01025622 Phase 1
46 Open Label Pilot Study Evaluating Minocycline in Patients With Primary Sclerosing Cholangitis (PSC) Completed NCT00630942 Phase 1 Minocycline
47 A Pilot Study of Xifaxan in Patients With Primary Sclerosing Cholangitis Completed NCT01695174 Phase 1 Xifaxan
48 A First in Human, Randomized, Double-Blind Study to Assess Safety, Tolerability, and Pharmacokinetics of Single, Ascending Doses of HTD1801 in Healthy Subjects Completed NCT03099603 Phase 1 HTD1801
49 Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis Completed NCT00004842 Phase 1 budesonide
50 A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis Completed NCT01085760 Phase 1 Vancomycin;Vancomycin;Metronidazole;Metronidazole;Vancomycin

Search NIH Clinical Center for Sclerosing Cholangitis

Genetic Tests for Sclerosing Cholangitis

Anatomical Context for Sclerosing Cholangitis

MalaCards organs/tissues related to Sclerosing Cholangitis:

41
Liver, Colon, T Cells, Testes, Neutrophil, Skin, Pancreas

Publications for Sclerosing Cholangitis

Articles related to Sclerosing Cholangitis:

(show top 50) (show all 5892)
# Title Authors PMID Year
1
Autoimmune Pancreatitis and IgG4-Related Disease: The Storiform Discovery to Treatment. 38
31363956 2019
2
Contributing factors and outcomes of burn-associated cholestasis. 38
31152758 2019
3
Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice. 38
31071368 2019
4
Quantitative spleen and liver volume changes predict survival of patients with primary sclerosing cholangitis. 38
31239109 2019
5
Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis. 38
31108158 2019
6
Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. 38
31250469 2019
7
Editorial: gut microbial profile associated with primary sclerosing cholangitis-what is new and how do we progress from here? 38
31414544 2019
8
Editorial: gut microbial profile associated with primary sclerosing cholangitis-what is new and how do we progress from here? Authors' reply. 38
31414547 2019
9
Differentiating pediatric autoimmune liver diseases by quantitative magnetic resonance cholangiopancreatography. 38
31422438 2019
10
Benign hilar bile duct strictures resected as perihilar cholangiocarcinoma. 38
31386198 2019
11
Successful treatment with rituximab of IgG4-related disease coexisting with adult-onset asthma and periocular xanthogranuloma. 38
31392499 2019
12
Cholestatic liver disease results increased production of reactive aldehydes and an atypical periportal hepatic antioxidant response. 38
31377417 2019
13
[Secondary cholangitis of the critically ill]. 38
31398769 2019
14
Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. 38
31165788 2019
15
Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. 38
30325540 2019
16
Family History Associates With Increased Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. 38
30267862 2019
17
Statin Use Is Associated With Improved Outcomes of Patients With Primary Sclerosing Cholangitis. 38
30448601 2019
18
The long-term outcomes of pediatric-onset primary sclerosing cholangitis: a single center experience in Japan. 38
31408920 2019
19
Characteristics and outcome of primary sclerosing cholangitis associated with inflammatory bowel disease in Asian children. 38
31409456 2019
20
Experience in Liver Transplantation Due to Primary Sclerosing Cholangitis: A Single Center Experience. 38
31405746 2019
21
Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. 38
30872395 2019
22
Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis-A Beautiful but Incomplete Story. 38
31205136 2019
23
Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: The Next Steps in This Promising Story. 38
31306151 2019
24
Predictive criteria of response to endoscopic treatment for severe strictures in primary sclerosing cholangitis. 38
30772328 2019
25
Pharmacologic management of primary sclerosing cholangitis: what's in the pipeline? 38
31257956 2019
26
The "pruned tree" appearance of primary sclerosing cholangitis. 38
31025068 2019
27
Impact of paediatric onset primary sclerosing cholangitis on clinical course and outcome of inflammatory bowel disease: a case-control population-based study in Finland. 38
31402720 2019
28
Microbiota as a cornerstone in the development of primary sclerosing cholangitis: paving the path for translational diagnostic and therapeutic approaches. 38
31028154 2019
29
Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis. 38
30131321 2019
30
British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. 38
31154395 2019
31
Variant and Specific Forms of Autoimmune Cholestatic Liver Diseases. 38
31165900 2019
32
Clinical Pathologic Mismatch in a TNF-α Inhibitor-Associated Drug Reaction 38
31424716 2019
33
Early detection of intrahepatic cholangiocarcinoma. 38
31372893 2019
34
Phosphatidylcholine Passes by Paracellular Transport to the Apical Side of the Polarized Biliary Tumor Cell Line Mz-ChA-1. 38
31430850 2019
35
Muscle performance and fatigue in compensated chronic liver disease. 38
31287334 2019
36
Impact of peroral cholangioscopy on the management of indeterminate biliary conditions: a multicentre prospective trial. 38
31281624 2019
37
[Paying attention to the diagnosis and treatment of IgG4-related sclerosing cholangitis]. 38
31269612 2019
38
Immunoglobulin G4-related hepatobiliary disease. 38
31358425 2019
39
Human biodistribution, dosimetry, radiosynthesis and quality control of the bile acid PET tracer [N-methyl-11C]cholylsarcosine. 38
31330413 2019
40
Clinical features of isolated proximal-type immunoglobulin G4-related sclerosing cholangitis. 38
30570170 2019
41
Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy. 38
31358424 2019
42
Correction: Activated T-Follicular Helper 2 Cells Are Associated With Disease Activity in IgG4-Related Sclerosing Cholangitis and Pancreatitis. 38
31313691 2019
43
Difficulty in the diagnosis of isolated immunoglobulin G4-related sclerosing cholangitis. 38
30920057 2019
44
Peroral cholangioscopy of programmed cell death-1 inhibitor-related sclerosing cholangitis: three case reports. 38
31340390 2019
45
Biliary features in liver histology of children with autoimmune liver disease. 38
31069759 2019
46
Diagnosis and management of IgG4-related disease. 38
31288262 2019
47
Large-duct cholangiopathies: aetiology, diagnosis and treatment. 38
31288256 2019
48
Prevalence of autoimmune diseases and clinical significance of autoantibody profile: Data from National Institute of Hygiene in Rabat, Morocco. 38
30807792 2019
49
Linear IgA Bullous Dermatosis Preceding the Diagnosis of Primary Sclerosing Cholangitis and Ulcerative Colitis: A Case Report. 38
30461424 2019
50
Precision medicine in primary sclerosing cholangitis. 38
31099965 2019

Variations for Sclerosing Cholangitis

Expression for Sclerosing Cholangitis

Search GEO for disease gene expression data for Sclerosing Cholangitis.

Pathways for Sclerosing Cholangitis

GO Terms for Sclerosing Cholangitis

Cellular components related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.97 TNF PRTN3 HLA-DRB1 HLA-B GPBAR1 GGT1
2 integral component of plasma membrane GO:0005887 9.87 TNF HLA-B CLDN1 CFTR CD40LG ABCB4
3 extracellular exosome GO:0070062 9.65 PRTN3 HLA-DRB1 HLA-B GPT GGT1 FUT2
4 intercellular canaliculus GO:0046581 9.26 ABCB4 ABCB11
5 cell surface GO:0009986 9.17 TNF HLA-DRB1 HLA-B CTSG CFTR CD40LG

Biological processes related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.65 TNF HLA-DRB1 HLA-B CTSG CD40LG
2 negative regulation of growth of symbiont in host GO:0044130 9.32 TNF CTSG
3 regulation of immunoglobulin secretion GO:0051023 8.96 TNF CD40LG
4 xenobiotic transport GO:0042908 8.85 NR1I2
5 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 8.8 NR1H4 HLA-DRB1 CFTR

Molecular functions related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.13 CFTR ABCB4 ABCB11
2 bile acid receptor activity GO:0038181 8.62 NR1H4 GPBAR1

Sources for Sclerosing Cholangitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....